

Anniina Färkkilä
Assistant Professor, Supervisor for doctoral programme
Department of Obstetrics and Gynecology
Department of Obstetrics and Gynecology
Doctoral Programme in Integrative Life Science
Doctoral Programme in Biomedicine
Doctoral Programme in Clinical Research
HUS Gynecology and Obstetrics
Type of address: Postal address.
Finland
Email: anniina.farkkila@helsinki.fi



Qualifications

Principal Investigator

Period : 10.12.2018 - * in Clinicum

Employment

Assistant Professor

Department of Obstetrics and Gynecology
University of Helsinki
Finland
1 May 2023 → present

Department of Obstetrics and Gynecology

University of Helsinki
Finland
8 Sept 2010 → present

Supervisor for doctoral programme

Doctoral Programme in Integrative Life Science
University of Helsinki
Finland
1 Jan 2024 → present

Supervisor for doctoral programme

Doctoral Programme in Biomedicine
University of Helsinki
Finland
1 Jan 2014 → present

Supervisor for doctoral programme

Doctoral Programme in Clinical Research
University of Helsinki
Finland
1 Jan 2014 → present

HUS Gynecology and Obstetrics

HYKS erva
Finland
1 Jan 2010 → present

Postdoctoral Fellow

Dana Farber Canc Inst, Dana Farber Cancer Center, Harvard University

United States
1 Apr 2017 → present

Publications

Chemotherapy induces myeloid-driven spatially confined T cell exhaustion in ovarian cancer

Launonen, I.-M., Niemiec, I., Hincapié-Otero, M., Erkan, E. P., Junquera, A., Afenteva, D., Falco, M. M., Liang, Z., Salko, M., Chamchougia, F., Szabo, A., Perez-Villatoro, F., Li, Y., Micoli, G., Nagaraj, A., Haltia, U.-M., Kahelin, E., Oikkonen, J., Hynninen, J. & Virtanen, A. & 6 others, Nirmal, A. J., Vallius, T., Hautaniemi, S., Sorger, P. K., Vähärautio, A. & Färkkilä, A., 9 Dec 2024, In: *Cancer Cell*. 42, 12, p. 2045-2063.e10 29 p.

Mathematical modeling framework enhances clinical trial design for maintenance treatment in oncology

Kozłowska, E., Haltia, U.-M., Puszyński, K. & Färkkilä, A., 29 Nov 2024, In: *Scientific Reports*. 14, 1, 11 p., 29721.

Randomized Phase II Study of Gemcitabine with or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses

Konstantinopoulos, P. A., Cheng, S. C., Lee, E. K., Da Costa, A. A. B. A., Gulhan, D., Wahner Hendrickson, A. E., Kochupurakkal, B., Kolin, D. L., Kohn, E. C., Liu, J. F., Penson, R. T., Stover, E. H., Curtis, J., Sawyer, H., Polak, M., Chowdhury, D., D'Andrea, A. D., Färkkilä, A., Shapiro, G. I. & Matulonis, U. A., 1 Apr 2024, In: *JCO Precision Oncology*. 8, e2300635.

Tracing back primed resistance in cancer via sister cells

Dai, J., Zheng, S., Falco, M. M., Bao, J., Eriksson, J., Pikkusaari, S., Forstén, S., Jiang, J., Wang, W., Gao, L., Perez-Villatoro, F., Dufva, O., Saeed, K., Wang, Y., Amiryousefi, A., Färkkilä, A., Mustjoki, S., Kauppi, L., Tang, J. & Vähärautio, A., 7 Feb 2024, In: *Nature Communications*. 15, 1, 14 p., 1158.

Kohdunrunkosyövän tarkentuva diagnostiikka ja hoito - immuno-onkologiset hoidot tuovat uutta toivoa

Färkkilä, A., Haltia, U.-M., Pasanen, A. & Lassus, H., 2024, In: *Duodecim*. 140, 19, p. 1633-1639 7 p.

Dysregulated germinal centre reaction with expanded T follicular helper cells in APECED lymph nodes

Hetemäki, I., Sarkkinen, J., Heikkilä, N., Drechsel, K., Mäyränpää, M. I., Färkkilä, A., Laakso, S., Mäkitie, O., Arstila, T. P. & Kekäläinen, E., 19 Dec 2023, In: *Journal of Allergy and Clinical Immunology*. 153, 5, p. 1445-1455 11 p.

The Emerging Role of the Single-Cell and Spatial Tumor Microenvironment in High-Grade Serous Ovarian Cancer

Launonen, I.-M., Vähärautio, A. & Färkkilä, A., Oct 2023, In: *Cold Spring Harbor Perspectives in Medicine*. 13, 10, 9 p., a041314.

Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes

Pikkusaari, S., Tumiati, M., Virtanen, A., Oikkonen, J., Li, Y., Perez-Villatoro, F., Muranen, T., Salko, M., Huhtinen, K., Kanerva, A., Koskela, H., Tapper, J., Koivisto-Korander, R., Joutsiniemi, T., Haltia, U.-M., Lassus, H., Hautaniemi, S., Färkkilä, A., Hynninen, J. & Hietanen, S. & 2 others, Carpen, O. & Kauppi, L., 15 Aug 2023, In: *Clinical Cancer Research*. 29, 16, p. 3110-3123 14 p.

Uusi työkalu räätälöityyn munasarjasyövän hoitoon

Pikkusaari, S., Tumiati, M., Virtanen, A., Oikkonen, J., Li, Y., Perez-Villatoro, F., Muranen, T., Salko, M., Huhtinen, K., Kanerva, A., Koskela, H., Tapper, J., Koivisto-Korander, R., Joutsiniemi, T., Haltia, U.-M., Lassus, H., Hautaniemi, S., Färkkilä, A., Hynninen, J. & Hietanen, S. & 2 others, Carpen, O. & Kauppi, L., 15 Aug 2023, In: *Duodecim*. 139, 9, p. 760 1 p.

STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer

Ding, L., Wang, Q., Martincuks, A., Kearns, M. J., Jiang, T., Lin, Z., Cheng, X., Qian, C., Xie, S., Kim, H.-J., Launonen, I.-M., Färkkilä, A., Roberts, T. M., Freeman, G. J., Liu, J. F., Konstantinopoulos, P. A., Matulonis, U., Yu, H. & Zhao, J. J., Jan 2023, In: *Journal for Immunotherapy of Cancer*. 11, 1, 15 p., e005627.

Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer

Launonen, I.-M., Lyytikäinen, N., Casado, J., Anttila, E. A., Szabo, A., Haltia, U.-M., Jacobson, C. A., Lin, J. R., Maliga, Z., Howitt, B. E., Strickland, K. C., Santagata, S., Elias, K., D'Andrea, A. D., Konstantinopoulos, P. A., Sorger, P. K. & Färkkilä, A., Dec 2022, In: Nature Communications. 13, 1, 14 p., 835.

Tumor-Derived Lysophosphatidic Acid Blunts Protective Type I Interferon Responses in Ovarian Cancer

Chae, C. S., Sandoval, T. A., Hwang, S. M., Park, E. S., Giovanelli, P., Awasthi, D., Salvagno, C., Emmanuelli, A., Tan, C., Chaudhary, V., Casado, J., Kossenkov, A. V., Song, M., Barrat, F. J., Holcomb, K., Romero-Sandoval, E. A., Zamarin, D., Pépin, D., D'Andrea, A. D. & Färkkilä, A. & 1 others, Cubillos-Ruiz, J. R., 1 Aug 2022, In: Cancer Discovery. 12, 8, p. 1904-1921 18 p.

Analysis of Non-Relapsed and Relapsed Adult Type Granulosa Cell Tumors Suggests Stable Transcriptomes during Tumor Progression

Andersson, N., Haltia, U.-M., Färkkilä, A., Wong, S. C., Eloranta, K., Wilson, D. B., Unkila-Kallio, L., Pihlajoki, M., Kyrönlähti, A. & Heikinheimo, M., Feb 2022, In: Current Issues in Molecular Biology. 44, 2, p. 686-698 13 p.

Munasarjasyövän immuunipuolustukselta piiloutumisen mekanismit paljastuvat

Launonen, I.-M., Lyytikäinen, N., Casado, J., Anttila, E., Szabo, A., Haltia, U.-M., Jacobson, C. A., Lin, J.-R., Maliga, Z., Howitt, B., Strickland, K., Santagata, S., Elias, K., D'Andrea, A., Konstantinopoulos, P., Sorger, P. & Färkkilä, A., 2022, In: Duodecim. 138, 5, p. 455 1 p.

Optimized detection of homologous recombination deficiency improves the prediction of clinical outcomes in cancer

Perez Villatoro, F. R., Oikkonen, J., Casado, J., Chernenko, A., Gulhan, D. C., Tumiaty, M., Li, Y., Lavikka, K. A., Hietanen, S., Hynninen, J., Haltia, U.-M., Tyrmi, J. S., Laivuori, H., Konstantinopoulos, P. A., Hautaniemi, S., Kauppi, L. & Färkkilä, A., 2022, In: npj precision oncology. 6, 1, 13 p., 96.

Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation

Duraiswamy, J., Turrini, R., Minasyan, A., Barras, D., Crespo, I., Grimm, A. J., Casado, J., Genolet, R., Benedetti, F., Wicky, A., Ioannidou, K., Castro, W., Neal, C., Moriot, A., Renaud-Tissot, S., Anstett, V., Fahr, N., Tanyi, J. L., Eiva, M. A. & Jacobson, C. A. & 16 others, Montone, K. T., Westergaard, M. C. W., Svane, I. M., Kandalaf, L. E., Delorenzi, M., Sorger, P. K., Färkkilä, A., Michielin, O., Zoete, V., Carmona, S. J., Foukas, P. G., Jr, D. J. P., Rusakiewicz, S., Doucey, M.-A., Laniti, D. D. & Coukos, G., 13 Dec 2021, In: Cancer Cell. 39, 12, p. 1623-+ 41 p.

A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer

Konstantinopoulos, P. A., da Costa, A. A. B. A., Gulhan, D., Lee, E. K., Cheng, S.-C., Hendrickson, A. E. W., Kochupurakkal, B., Kolin, D. L., Kohn, E. C., Liu, J. F., Stover, E. H., Curtis, J., Tayob, N., Polak, M., Chowdhury, D., Matulonis, U. A., Färkkilä, A., D'Andrea, A. D. & Shapiro, G., 22 Sept 2021, In: Nature Communications. 12, 1, 8 p., 5574.

Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells

Färkkilä, A., Rodriguez, A., Oikkonen, J., Gulhan, D. C., Huy Nguyen, Dominguez, J., Ramos, S., Mills, C. E., Perez-Villatoro, F., Lazaro, J.-B., Zhou, J., Clairmont, C. S., Moreau, L. A., Park, P. J., Sorger, P. K., Hautaniemi, S., Frias, S. & D'Andrea, A. D., 15 May 2021, In: Cancer Research. 81, 10, p. 2774-2787 14 p.

Agile workflow for interactive analysis of mass cytometry data

Casado, J., Lehtonen, O., Rantanen, V., Kaipio, K., Pasquini, L., Häkkinen, A., Petrucci, E., Hynninen, J., Hietanen, S., Carpen, O., Biffoni, M., Färkkilä, A. & Hautaniemi, S., 1 May 2021, In: Bioinformatics. 37, 9, p. 1263-1268 6 p.

Adult-type granulosa cell tumor of the ovary: a FOXL2-centric disease

Pilsworth, J. A., Cochrane, D. R., Neilson, S. J., Moussavi, B. H., Lai, D., Munzur, A. D., Senz, J., Wang, Y. K., Zareian, S., Bashashati, A., Wong, A., Keul, J., Staebler, A., van Meurs, H. S., Horlings, H. M., Kommoss, S., Kommoss, F., Oliva, E., Färkkilä, A. E. M. & Gilks, B. & 1 others, Huntsman, D. G., May 2021, In: The Journal of Pathology. Clinical Research. 7, 3, p. 243-252 10 p.

Procaspase-Activating Compound-1 Synergizes with TRAIL to Induce Apoptosis in Established Granulosa Cell Tumor Cell Line (KGN) and Explant Patient Granulosa Cell Tumor Cells In Vitro

Crosley, P., Färkkilä, A., Jenner, A., Burlot, C., Cardinal, O., Potts, K., Agopsowicz, K., Pihlajoki, M., Heikinheimo, M., Craig, M., Fu, Y. & Hitt, M., May 2021, In: International Journal of Molecular Sciences. 22, 9, 17 p., 4699.

Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy

Iyer, S., Zhang, S., Yucel, S., Horn, H., Smith, S. G., Reinhardt, F., Hoefsmit, E., Assatova, B., Casado, J., Meinsohn, M.-C., Barrasa, M. I., Bell, G. W., Perez-Villatoro, F., Huhtinen, K., Hynninen, J., Oikkonen, J., Galhenage, P. M., Pathania, S., Hammond, P. T. & Neel, B. G. & 3 others, Färkkilä, A., Pepin, D. & Weinberg, R. A., Feb 2021, In: Cancer Discovery. 11, 2, p. 384-407 24 p.

MYC Promotes Bone Marrow Stem Cell Dysfunction in Fanconi Anemia

Rodriguez, A., Zhang, K., Färkkilä, A., Filiatrault, J., Yang, C., Velazquez, M., Furutani, E., Goldman, D. C., Garcia de Teresa, B., Garza-Mayen, G., McQueen, K., Sambel, L. A., Molina, B., Torres, L., Gonzalez, M., Vadiillo, E., Pelayo, R., Fleming, W. H., Grompe, M. & Shimamura, A. & 5 others, Hautaniemi, S., Greenberger, J., Frias, S., Parmar, K. & D'Andrea, A. D., 7 Jan 2021, In: Cell Stem Cell. 28, 1, p. 33-+ 23 p.

Inhibition of TGF beta 1 and TGF beta 3 promotes hematopoiesis in Fanconi anemia

Rodriguez, A., Yang, C., Furutani, E., Teresa, B. G. D., Velazquez, M., Filiatrault, J., Sambel, L. A., Phan, T., Flores-Guzman, P., Sanchez, S., Orozco, A. M., Mayani, H., Bolukbasi, O. V., Färkkilä, A., Epperly, M., Greenberger, J., Shimamura, A., Frias, S., Grompe, M. & Parmar, K. & 1 others, D'Andrea, A. D., Jan 2021, In: Experimental Hematology. 93, p. 70-U53 19 p.

DNA-vaurioiden hyödyntäminen munasarjasyövän hoidossa

Färkkilä, A., Launonen, I.-M., Perez, F., Virtanen, A. & Lassus, H., 2021, In: Duodecim. 137, 21, p. 2287-2295 9 p.

PARP:n estäjät mullistavat munasarjasyövän hoidon : hoidosta eniten hyötyvät voidaan tunnistaa geneettisen testauksen avulla

Färkkilä, A., Lassus, H. & Loukovaara, M., 2021, In: Duodecim. 137, 21, p. 2228-2230 3 p.

Functional Profiling of FSH and Estradiol in Ovarian Granulosa Cell Tumors

Haltia, U.-M., Pihlajoki, M., Andersson, N., Mäkinen, L., Tapper, J., Cervera, A., Horlings, H. M., Turpeinen, U., Anttonen, M., Bützow, R., Unkila-Kallio, L., Carpen, O., Wilson, D. B., Heikinheimo, M. & Färkkilä, A., Apr 2020, In: Journal of the Endocrine Society. 4, 4, 20 p., 034.

Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer

Färkkilä, A., Gulhan, D. C., Casado, J., Jacobson, C. A., Nguyen, H., Kochupurakkal, B., Maliga, Z., Yapp, C., Chen, Y.-A., Schapiro, D., Zhou, Y., Graham, J. R., Dezube, B. J., Munster, P., Santagata, S., Garcia, E., Rodig, S., Lako, A., Chowdhury, D. & Shapiro, G. & 7 others, Matulonis, U. A., Park, P. J., Hautaniemi, S., Sorger, P. K., Swisher, E. M., D'Andrea, A. D. & Konstantinopoulos, P. A., 19 Mar 2020, In: Nature Communications. 11, 1, 13 p., 1459.

Virtual clinical trials identify effective combination therapies in ovarian cancer

Kozłowska, E., Vallius, T., Hynninen, J., Hietanen, S., Färkkilä, A. & Hautaniemi, S., 10 Dec 2019, In: Scientific Reports. 9, 9 p., 18678.

Open Source Infrastructure for Health Care Data Integration and Machine Learning Analyses

Isoviita, V.-M., Salminen, L., Azar, J., Lehtonen, R., Roering, P., Carpen, O., Hietanen, S., Grénman, S., Hynninen, J., Färkkilä, A. & Hautaniemi, S., 27 Aug 2019, In: JCO Clinical Cancer Informatics. 3, 16 p.

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma

Konstantinopoulos, P. A., Waggoner, S., Vidal, G. A., Mita, M., Moroney, J. W., Holloway, R., Van Le, L., Sachdev, J. C., Chapman-Davis, E., Colon-Otero, G., Penson, R. T., Matulonis, U. A., Kim, Y. B., Moore, K. N., Swisher, E. M., Färkkilä, A., D'Andrea, A., Stringer-Reasor, E., Wang, J. & Buerstatte, N. & 5 others, Arora, S., Graham, J. R., Bobilev, D., Dezube, B. J. & Munster, P., Aug 2019, In: JAMA Oncology. 5, 8, p. 1141-1149 9 p.

Prospective Longitudinal ctDNA Workflow Reveals Clinically Actionable Alterations in Ovarian Cancer

Oikkonen, J., Zhang, K., Salminen, L., Schulman, I., Lavikka, K., Andersson, N., Ojanperä, E., Hietanen, S., Grénman, S., Lehtonen, R., Huhtinen, K., Carpén, O., Hynninen, J., Färkkilä, A. & Hautaniemi, S., 3 May 2019, In: *JCO Precision Oncology*. 3, 3, p. 1-12 12 p.

Evaluation of risk factors for oral infection with potential for spread in a 1-year cohort study

Farkkila, E., Rautemaa-Richardson, R., Färkkilä, A., Grönholm, L. & Lauhio, A., Feb 2019, In: *Clinical Oral Investigations*. 23, 2, p. 905-911 7 p.

Other Primary Malignancies Among Women With Adult-Type Ovarian Granulosa Cell Tumors

Bryk, S., Pukkala, E., Färkkilä, A., Heikinheimo, M., Unkila-Kallio, L. & Riska, A., Oct 2018, In: *International Journal of Gynecological Cancer*. 28, 8, p. 1529-1534 6 p.

A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients

Tumiati, M., Hietanen, S., Hynninen, J., Pietilä, E., Färkkilä, A., Kaipio, K., Roering, P., Huhtinen, K., Alkods, A., Li, Y., Lehtonen, R., Erkan, E. P., Tuominen, M. M., Lehti, K., Hautaniemi, S. K., Vähärautio, A., Grenman, S., Carpen, O. & Kauppi, L., 15 Sept 2018, In: *Clinical Cancer Research*. 24, 18, p. 4482-4493 12 p.

Mathematical Modeling Predicts Response to Chemotherapy and Drug Combinations in Ovarian Cancer

Kozłowska, E., Färkkilä, A., Vallius, T., Carpen, O., Kempainen, J., Grenman, S., Lehtonen, R., Hynninen, J., Hietanen, S. & Hautaniemi, S., 15 Jul 2018, In: *Cancer Research*. 78, 14, p. 4036-4044 9 p.

TERT promoter mutation in adult granulosa cell tumor of the ovary

Pilsworth, J. A., Cochrane, D. R., Xia, Z., Aubert, G., Färkkilä, A. E. M., Horlings, H. M., Yanagida, S., Yang, W., Lim, J. L. P., Wang, Y. K., Bashashati, A., Keul, J., Wong, A., Norris, K., Brucker, S. Y., Taran, F.-A., Krämer, B., Staebler, A., van Meurs, H. & Oliva, E. & 6 others, Shah, S. P., Kommos, S., Kommos, F., Gilks, C. B., Baird, D. M. & Huntsman, D. G., Jul 2018, In: *Modern Pathology*. 31, 7, p. 1107-1115 9 p.

Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells

Haltia, U.-M., Andersson, N., Yadav, B., Farkkila, A., Kuleskiy, E., Kankainen, M., Tang, J., Butzow, R., Riska, A., Leminen, A., Heikinheimo, M., Kallioniemi, O., Unkila-Kallio, L., Wennerberg, K., Aittokallio, T. & Anttonen, M., Mar 2017, In: *Gynecologic Oncology*. 144, 3, p. 621-630 10 p.

FOX L2 402C > G Mutation Can Be Identified in the Circulating Tumor DNA of Patients with Adult-Type Granulosa Cell Tumor

Farkkila, A., McConechy, M. K., Yang, W., Talhouk, A., Ng, Y., Lum, A., Morin, R. D., Bushell, K., Riska, A., McAlpine, J. N., Gilks, C. B., Unkila-Kallio, L., Anttonen, M. & Huntsman, D. G., Jan 2017, In: *Journal of Molecular Diagnostics*. 19, 1, p. 126-136 11 p.

Roles of human epididymis protein 4, carbohydrate antigen 125, inhibin B and anti-Mullerian hormone in the differential diagnosis and follow-up of ovarian granulosa cell tumors

Haltia, U.-M., Hallamaa, M., Tapper, J., Hynninen, J., Alfthan, H., Kalra, B., Ritvos, O., Heikinheimo, M., Unkila-Kallio, L., Perheentupa, A. & Farkkila, A., Jan 2017, In: *Gynecologic Oncology*. 144, 1, p. 83-89 7 p.

Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary

Farkkila, A., Haltia, U.-M., Tapper, J., McConechy, M. K., Huntsman, D. G. & Heikinheimo, M., 2017, In: *Annals of Medicine*. 49, 5, p. 435-447 13 p.

Characteristics and outcome of recurrence in molecularly defined adult-type ovarian granulosa cell tumors

Bryk, S. S., Färkkilä, A., Butzow, R., Leminen, A., Johanna, T., Heikinheimo, M., Unkila-Kallio, L. & Riska, A., Dec 2016, In: *Gynecologic Oncology*. 143, 3, p. 571-577 7 p.

Molecularly Defined Adult Granulosa Cell Tumor of the Ovary: The Clinical Phenotype

McConechy, M. K., Farkkila, A., Horlings, H. M., Talhouk, A., Unkila-Kallio, L., van Meurs, H. S., Yang, W., Rozenberg, N., Andersson, N., Zaby, K., Bryk, S., Butzow, R., Halfwerk, J. B. G., Hooijer, G. K. J., van de Vijver, M. J., Buist, M. R., Kenter, G. G., Brucker, S. Y., Kramer, B. & Staebler, A. & 6 others, Bleeker, M. C. G., Heikinheimo, M., Kommoss, S., Gilks, C. B., Anttonen, M. & Huntsman, D. G., Nov 2016, In: Journal of the National Cancer Institute. 108, 11, 5 p., 134.

Circulating levels of TNF-related apoptosis inducing-ligand are decreased in patients with large adult-type granulosa cell tumors-implications for therapeutic potential

Farkkila, A., Zauli, G., Haltia, U.-M., Pihlajoki, M., Unkila-Kallio, L., Secchiero, P. & Heikinheimo, M., Sept 2016, In: Tumor Biology. 37, 9, p. 11909-11916 8 p.

GATA factors in endocrine neoplasia

Pihlajoki, M., Farkkila, A., Soini, T., Heikinheimo, M. & Wilson, D. B., Feb 2016, In: Molecular and Cellular Endocrinology. 421, C, p. 2-17 16 p.

Munasarjan granulosa solukasvaimen diagnostiikka ja seuranta tarkentuvat

Färkkilä, A. & Unkila-Kallio, L., 2016, In: Duodecim. 132, 11, p. 1033-1039 7 p.

Toisen raskauskolmanneksen samanaikainen kohdunulkoinen ja -sisäinen raskaus on vakava raskauskomplikaatio

Färkkilä, A. & Laitinen, L., 2016, In: Duodecim. 132, 8, p. 730-733 4 p.

The clinical utility of serum anti-Müllerian hormone in the follow-up of ovarian adult-type granulosa cell tumorsA comparative study with inhibin B

Farkkila, A., Koskela, S., Bryk, S., Alfthan, H., Butzow, R., Leminen, A., Puistola, U., Tapanainen, J. S., Heikinheimo, M., Anttonen, M. & Unkila-Kallio, L., 1 Oct 2015, In: International Journal of Cancer. 137, 7, p. 1661-1671 11 p.

Clinical characteristics and survival of patients with an adult-type ovarian granulosa cell tumor: a 56-year single-center experience.

Bryk, S. S., Färkkilä, A., Butzow, R., Anttonen, M., Heikinheimo, M., Leminen, A., Riska, A. & Unkila-Kallio, L., 25 Jan 2015, In: International Journal of Gynecological Cancer. 25, 1, p. 33-41 9 p.

Sensitivity of human granulosa cell tumor cells to epidermal growth factor receptor inhibition

Andersson, N., Anttonen, M., Farkkila, A., Pihlajoki, M., Butzow, R., Unkila-Kallio, L. & Heikinheimo, M., Apr 2014, In: Journal of Molecular Endocrinology. 52, 2, p. 223-234 12 p.

FOXL2, GATA4, and SMAD3 Co-Operatively Modulate Gene Expression, Cell Viability and Apoptosis in Ovarian Granulosa Cell Tumor Cells

Anttonen, M., Pihlajoki, M., Andersson, N., Georges, A., L'Hote, D., Vattulainen, S., Farkkila, A., Unkila-Kallio, L., Veitia, R. A. & Heikinheimo, M., 9 Jan 2014, In: PLoS One. 9, 1, 8 p., 85545.

HER2 and GATA4 are new prognostic factors for early-stage ovarian granulosa cell tumor-a long-term follow-up study

Färkkilä, A., Andersson, N. K., Butzow, R., Leminen, A., Heikinheimo, M., Anttonen, M. & Unkila-Kallio, L., 2014, In: Cancer medicine . 3, 3, p. 526-536 11 p.

Seerumin anti-Müllerin hormonin (AMHn) kliininen käyttö : lisääntymisestä granulosa solukasvaimiin

Färkkilä, A. & Anttonen, M., 2014, In: Klin lab : kliinisen laboratorioalan julkaisu : SKKY:n jäsenlehti.. 31, 3, p. 36-39 4 p.

Klinisk användning av serum Anti-Müllerskt Hormon (AMH): Från reproduktion till granulosa celltumörer

Färkkilä, A. & Anttonen, M., 2012, In: Klinisk biokemi i Norden.. 24, 1, p. 50-54 5 p.

Molecular studies on pathogenesis, prognostic factors, and new treatment options for ovarian granulosa cell tumors

Färkkilä, A., 2012, Helsinki: [A. Färkkilä]. 80 p.

Anti-Müllerian hormone inhibits growth of AMH type II receptor-positive human ovarian granulosa cell tumor cells by activating apoptosis

Anttonen, M., Färkkilä, A., Tauriala, H., Kauppinen, M., MacLaughlin, D. T., Unkila-Kallio, L., Butzow, R. & Heikinheimo, M., 2011, In: Laboratory Investigation. 91, 11, p. 1605-1614 10 p.

Serum Vascular Endothelial Growth Factor A (VEGF) Is Elevated in Patients with Ovarian Granulosa Cell Tumor (GCT), and VEGF Inhibition by Bevacizumab Induces Apoptosis in GCT in Vitro

Färkkilä, A., Pihlajoki, M., Tauriala, H., Butzow, R., Leminen, A., Unkila-Kallio, L., Heikinheimo, M. & Anttonen, M., 2011, In: Journal of Clinical Endocrinology and Metabolism. 96, 12, p. E1973-E1981 9 p.

Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 are highly expressed in ovarian granulosa cell tumors

Färkkilä, A., Anttonen, M. T., Pociuviene, J., Leminen, A., Butzow, R., Heikinheimo, M. & Unkila-Kallio, L., 2011, In: European Journal of Endocrinology. 164, 1, p. 115-122 8 p.

Vascular endothelial growth factor-C accelerates diabetic wound healing

Saaristo, A., Tammela, T., Färkkilä, A., Kärkkäinen, M., Suominen, E., Ylä-Herttua, S. & Alitalo, K., 2006, In: The American Journal of Pathology. 169, 3, p. 1080-1087 8 p.

Prizes

Eero Saksela palkinto

Färkkilä, A. (Recipient), 23 Sept 2022

Seth Wichmann palkinto

Färkkilä, A. (Recipient), 15 Nov 2018

Projects

Discovery and therapeutic exploitation of immunological vulnerabilities in high grade serous ovarian cancer

Färkkilä, A. (Project manager)

01/01/2019 → ...

Discovery and therapeutic exploitation of immunological vulnerabilities in ovarian cancer

Färkkilä, A. (Project manager), Kang, Z. (Participant), Niemiec, I. (Participant), Nagaraj, A. (Participant), Perez Villatoro, F. R. (Participant), Chernenko, A. (Participant) & Shah, S. (Participant)

01/01/2021 → 31/12/2023

Discovery and therapeutic exploitation of immunological vulnerabilities in ovarian cancer

Färkkilä, A. (Project manager), Casado, J. (Participant), Perez Villatoro, F. R. (Participant), Pietilä, E. (Participant), Nagaraj, A. (Participant) & Launonen, I.-M. P. (Participant)

SUOMEN AKATEMIA

01/01/2021 → 31/12/2024

EU_ERC_Färkkilä Anniina_Space_101076096

Färkkilä, A. (Project manager), Chernenko, A. (Participant), Hincapie Otero, M. M. (Participant), Junquera Mencía, A. (Participant), Kang, Z. (Participant), Niemiec, I. (Participant), Palomino Echeverria, S. (Participant) & Shah, S. (Participant)

European Commission Joint Research Centre

01/02/2023 → 31/01/2028

Munasarjasyövän täsmälääketiede immunogenomisen profiloinnin avulla

Färkkilä, A. (Project manager), Jukonen, J. J. J. (Participant) & Nagaraj, A. (Participant)

Suomen Akatemia Projektilaskutus

01/09/2022 → 31/08/2026

Syöpäsäätiö 2024-26_Färkkilä

Färkkilä, A. (Project manager) & Szabó, A. (Participant)

Syöpäsäätiö sr Cancerstiftelsen sr
01/01/2024 → 31/12/2026

SELECTED INTERNATIONAL INVITED TALKS

09/2021AACR Virtual special conference: Ovarian cancer 2021
04/2021University of Minnesota Department of Pharmacology Spring seminar 2021 (virtual)
03/2021Annual meeting 2021, NSGO, Copenhagen, Denmark (virtual)
06/2020Ludwig meeting, The Ludwig Center of Harvard Medical School, Boston, USA
01/2020Annual meeting, Stand Up to Cancer, Santa Monica, CA, USA
11/2019Annual meeting 2019, Mexican society of Human Genetics, Tuxtla, Chiapas, Mexico
06/2019Annual meeting 2019, British Society for Gynecologic Oncology, Cambridge, UK
06/2016Annual meeting 2016, Nordic Federation of Obstetrics and Gynecologists, Helsinki, Finland
ORGANISATION OF SCIENTIFIC MEETINGS (as a Coordinator)
23.08.2021Special seminar on Highly Multiplexed imaging and Spatial proteomics, UH and HUH
2019 - Bioimaging Informatics working group, monthly seminars, ONCOSYS Research Program, HUH
18.11.2020Advances in the treatment of Gynecologic cancers 2020, Virtual Symposium, UH and HUH
18.11.2019Biomedicum Helsinki invited lecturer Professor David Huntsman, Vancouver, BC, Canada
26.08.2019Advances in Precision Oncology and Biomarkers in Clinical Trials Symposium, UH and HUH
26.01.2017Clinical data- workshop, Hercules EU consortium

INSTITUTIONAL RESPONSIBILITIES

2021-Student mentor for MD-PhD program, UH, Finland
09/2021Official PhD Opponent, University of Bergen, Norway
2022Thesis committee, Santeri Pekola, B.Med
2021Thesis committee, Essi Friman, MD
2020Thesis committee, Michaela Feodoroff, M.Sc
2020Thesis committee, Wafa Wahbi, M.Sc
2020Thesis committee, Petra Nygren, B.Med
2019Thesis committee, Sara Khamaiseh, M.Sc
2016Pre-examiner, Susanna Jonkka M.Sc, Master's Thesis
2016 - 2020Thesis committee, Liina Salminen MD
2015Thesis committee, Jaana Tolvanen M.Sc
2015Thesis committee, Elina Pietilä M.Sc
2016Pre-examiner, Susanna Jonkka M.Sc, Master's Thesis, UH, Finland

EXPERT PANELS AND REVIEWING ACTIVITY

2021 - Board member, European Network of gynecological clinical trials (ENTOG) and Gynecologic Cancer Inter Group (GCIG)
2021 - Board member, Finnish Cancer Center (FICAN) National Molecular tumor board
2021 - Board member, GSK Advisory Board "Evolving Role of Homologous Recombination Deficiency (HRD) Testing in the Treatment of Ovarian Cancer"
2020 - Board member, Translational working group, Nordic Society for Gynecologic Oncology (NSGO) Clinical trials unit
2020 - Consortium member, Nordic consortium for HRD biomarker development
2020Review panel member, National Autonomous University of Mexico, Mexico
2019 - Board member, Ethical board, Helsinki University Hospital, Helsinki, Finland
2015- Reviewer for 15 scientific journals such as Nature, Annals of Oncology Nature Communications, Cancer Research, International Journal of Cancer, Gynecologic Oncology, Cancers

MAJOR COLLABORATIONS

George Coukos Functional states of tumor-infiltrating lymphocytes in high-grade serous ovarian cancer. University of Lausanne, Lausanne, Switzerland
Robert WeinbergImmune microenvironments and therapeutic vulnerabilities of novel syngeneic mouse models of ovarian cancer. Whitehead Institute, Boston, MA, USA
David HuntsmanMolecular diagnostics of ovarian granulosa cell tumors. University of British Columbia, Vancouver, BC, Canada

CAREER BREAKS

01.12.2009 - 31.8.2010Maternity leave (9 months)
10.08.2012 - 31.4.2013Maternity leave (9 months)